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ONE SENTENCE SUMMARY: A Tribbles 2 pseudokinase small molecule screen led to the 
identification of EGFR/HER2 inhibitors that alter the stability of TRIB2 in vitro and induce rapid ‘on-
target’ degradation of TRIB2 in human cancer cells. 
ABSTRACT:  
A major challenge associated with biochemical and cellular analysis of pseudokinases is a lack of 
target-validated small molecule ligands with which to probe function. Human Tribbles 2 (TRIB2) is a 
cancer-associated pseudokinase with a diverse interactome, including the canonical AKT signaling 
module. There is substantial evidence that human TRIB2 is a therapeutic target in both solid tumors 
and blood cancers. The unusual TRIB2 pseudokinase domain contains a unique cysteine-rich C-helix 
and interacts with a conserved peptide motif in its own C-terminal tail, which also supports interaction 
with cellular E3 ubiquitin ligases. In this study, we demonstrate that TRIB2 is a target for previously 
described small molecule protein kinase inhibitors, which were originally designed to inhibit the 
canonical catalytic domain of the epidermal growth factor receptor/human epidermal growth factor 
receptor 2 (EGFR/HER2) tyrosine kinases. Using a thermal-shift assay (TSA), we discovered TRIB2 
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ligands within the Published Kinase Inhibitor Set (PKIS), and employed a drug repurposing approach 
to classify compounds that either stabilize or destabilize TRIB2 in vitro. Remarkably, TRIB2 
destabilizing agents, including the covalent drug afatinib, lead to rapid TRIB2 degradation in human 
cells, eliciting tractable effects on signaling and survival. Our data reveal the first drug-leads for 
development of TRIB2-degrading ligands, which will also be invaluable for unravelling the cellular 
mechanisms of TRIB2-based signaling. Our study highlights that small molecule-induced protein 
downregulation through drug ‘off-targets’ might be relevant for other inhibitors that serendipitously 
target pseudokinases. 
KEYWORDS: allosteric, inhibitor, Tribbles 2, ligand, pseudokinase, pseudoenzyme, kinase  
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INTRODUCTION:  
The human protein kinome encodes ~60 protein pseudokinases, which lack at-least one conventional 
catalytic residue, but often control rate-limiting signaling outputs within cellular networks [1]. Like 
canonical kinases, pseudokinases drive conformation-dependent signaling associated with both 
physiology and disease [2, 3]. The human ‘pseudokinome’ includes cancer-associated signaling 
proteins such as HER3, JAK2 (JH2 domain) and TRIB2, which have historically received much less 
attention compared to their conventional, catalytically-active, counterparts even though pseudokinase 
domains represent rational targets for drug discovery [4]. Discovering or repurposing biologically 
and/or clinically-active ligands that target atypical-conformations of canonical kinases or 
pseudokinases, is an area of active research [2, 3, 5-9]. Moreover, the burgeoning pseudokinase field 
is strongly placed to benefit from the decades of research undertaken on canonical protein kinases, 
which has seen the approval of over 40 kinase inhibitors for human cancer and inflammatory diseases 
[10, 11].  This includes understanding how ATP-competitive, allosteric or covalent inhibitors might 
influence pseudokinase-based signaling mechanisms that are relevant to health and disease [3, 12]. 
The three human Tribbles (TRIB) pseudokinases, and the related pseudokinase STK40/Sgk495, are 
homologues of the Drosophila melanogaster pseudokinase termed Tribbles, which controls ovarian 
border cell and neuronal stem cell physiology [13, 14]. Tribbles, TRIB1, 2 and 3 and STK40 proteins, 
all contain a catalytically-impaired pseudokinase domain. Adaptions in the pseudokinase fold, 
including a highly unusual C-helix, are thought to support a competitive regulatory interaction in cis 
with a unique C-terminal tail DQLVP motif [15-17]. Through a still obscure mechanism, TRIB and 
STK40 function as adaptor proteins that recruit ubiquitin E3 ligases, such as COP1, through 
interaction with the conserved C-tail peptide [15, 17], which is also required for signaling and cellular 
transformation [18]. Mechanistically, Tribbles signaling outputs are controlled through the 
ubiquitylation and subsequent proteasomal destruction of Tribbles ‘pseudosubstrates’, such as 
vertebrate C/EBP, CDC25C and Acetyl CoA carboxylase [19-21]. 
A longstanding goal in cancer research is drug-induced degradation of oncogenic proteins. Progress 
towards this objective has been transformed by the synthesis of proteolysis-targeting chimeras 
(PROTACs), which induce proteasome-dependent degradation of their targets. Multifunctional small 
molecule PROTACS often possess ligand-binding regions derived from kinase inhibitors [22, 23], and 
multiple classes of non-PROTAC kinase inhibitor also induce kinase target degradation, although 
typically at higher (micromolar) concentrations than those required for enzymatic inhibition [7]. 
Recent reports also disclose classes of covalent ligands that bind and disable cysteine (Cys)-
containing small G-proteins such as mutant human RAS, permitting covalent inactivation of this 
previously ‘undruggable’ oncoprotein [24, 25]. Cys residues are widespread and highly conserved in 
kinases [26] and the conservation of Cys residues both inside and outside the catalytic domain 
provides kinome-wide opportunities for exploitation using chemical biology [27]. In this context, 
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covalent targeting methodologies involving compound-accessible Cys residues in kinases [8, 28-31] 
and pseudokinases [3], have attracted significant attention for small molecule design, due to the 
potential for gains in target specificity and durability of responses, combined with tractability in 
experimental systems.  
Tribbles pseudokinases are implicated in a huge variety of physiological signaling pathways, often in 
the context of protein stability, but also through regulation of key modules, such as the canonical 
AKT pathway [32]. TRIB2 is also implicated in the aetiology of human cancers, including leukemias, 
melanoma, lung and liver cancer [33]. In particular, TRIB2 is a potential drug target in subsets of 
acute myeloid and lymphoid leukemia (AML and ALL), which are in urgent need of targeted 
therapeutics to help treat untargeted or drug-resistant patient populations [34]. TRIB2 protein levels 
have also been linked to drug-resistance mechanisms, where an ability to modulate the pro-survival 
AKT signaling module underlies a central regulatory role in cell proliferation, differentiation, 
metabolism and apoptosis [32, 35-39].  
In this paper, we report that the low-affinity TRIB2 ATP-binding site [40] is druggable with small 
molecules previously described as ATP-competitive pan-EGFR/HER2 kinase inhibitors. Biochemical 
analysis confirms the existence of distinct ligand-induced TRIB2 conformations and a compound 
screen identifies known EGFR/HER2 inhibitors that stabilize or destabilize TRIB2 in vitro. TRIB2 
ligands include the clinical breast cancer therapeutic lapatinib/Tykerb [41] and the approved 
irreversible electrophilic covalent inhibitors afatinib/Giotrif [42, 43] and neratinib/Nerlynx [44, 45]. 
In the case of these two destabilizing agents, binding leads to uncoupling of the pseudokinase domain 
from its own C-terminal tail. Consistently, afatinib exposure leads to rapid TRIB2 degradation in 
cells, driven by an interaction with the Cys-rich pseudokinase domain, which interferes with AKT 
signaling and decreases cell survival in a TRIB2-expressing leukemia model. The availability of 
target-validated ligands that act as rapid TRIB2 pseudokinase down-regulators via a direct effect on 
the pseudokinase, represents a new way to evaluate TRIB2 physiology and cell signaling. It might 
also have a broader impact on the rapidly developing pseudoenzyme field [46], where the concept of 
pseudokinase destabilization or elimination by targeted kinase ‘inhibitors’ [7] has a number of 
potentially useful applications.  
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RESULTS: 
Analysis of human TRIB2 using a thermal stability assay 
Human TRIB2 differs from TRIB1, TRIB3 and STK40 in the pseudokinase domain due to a Cys-rich 
region at the end of the 3 Lys-containing motif leading into the truncated C-helix in the N-lobe 
(Fig. 1A, top).  We developed a differential scanning fluorimetry (DSF) assay [47-49] to examine 
thermal stability of full-length (1-343) His-tagged TRIB2 proteins, and compared it either to full-
length cAMP-dependent protein kinase (PKAc) catalytic subunit, which is a model for canonical 
kinases, or full-length C104Y TRIB2, in which Cys104 was replaced with the Tyr residue conserved in 
human TRIB1 and TRIB3 (Fig. 1A). Proteins were purified to homogeneity (Fig. 1A, bottom) and 
thermal stability based on unfolding profiles were determined for each protein (reported as a Tm value, 
Fig. 1B). As previously demonstrated [40], TRIB2 (Tm = ~39 °C) was much less thermostable than 
the canonical protein kinase (PKA, Tm = 46.3 °C). Remarkably, the C104Y single substitution 
induced stabilization of TRIB2, with the Tm value increasing to ~49 °C, comparable to that of human 
TRIB1 [15], suggesting an important structural role for this unique Cys residue in TRIB2 (un)folding 
dynamics. To confirm that recombinant TRIB2 binds to a known physiological target, we 
demonstrated that GST-tagged TRIB2 interacted preferentially with catalytically inactive (non Thr308-
phosphorylated) AKT1 in vitro (Fig. 1C). Consistent with a functional regulatory interaction between 
TRIB2 and AKT in cells [50], transient overexpression of TET-inducible FLAG-tagged TRIB2 in 
HeLa cells led to a large increase in endogenous AKT phosphorylation at the hydrophobic motif 
(Ser473, Fig. 1D), an established marker for AKT catalytic activity and generation of a downstream 
cellular anti-apoptotic signal [51].  
A DSF screen for TRIB2 ligands using a kinase inhibitor library 
The ability of full-length recombinant human TRIB2 to bind to adenosine triphosphate (ATP) in the 
presence of EDTA [40, 48] confirms that a vestigial nucleotide-binding site is present within the 
pseudokinase domain. Moreover, our previous work established that an analogue-sensitive (F190G) 
TRIB2 variant could be stabilized by bulky pyrimidine analogues in vitro [40].  To discover drug-like 
ligands for WT (full-length) TRIB2, we screened the Published Kinase Inhibitor Set (PKIS), a 
collection of high-quality class-annotated kinase inhibitors [52]. We enforced cut off values of ~Tm 
= < -2 °C and > +3.5 °C (therefore eliminating ~97% of the library) to define ‘hit’ compounds that 
possessed the ability to destabilize or stabilize TRIB2 in a thermal stability assay (TSA) at a 1:4 
TRIB2:compound molar ratio (Fig. 1E and table S1). The top ‘stabilizing’ compound identified was 
GW693881A, a dual EGFR/HER2 thienopyrimdine inhibitor with a Tm of +4.7 °C. The top 
‘destabilizing’ compound was GW804482X, a thiophene polo-like kinase (PLK) inhibitor that 
induced a Tm of - 3.4 °C (Fig. 1E, red symbols). Most of the top stabilizing and destabilizing 
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compounds belonged to well-known ATP-competitive pyrimidine or quinazoline EGFR/HER2 
chemotypes (fig. S1) [53-55], suggesting broad structural cross-reactivity between TRIB2 and a 
ligand-binding EGFR/HER2 conformation. To build upon these findings, we screened a larger panel 
of known dual EGFR/HER2 inhibitors (fig. S2), and established that the clinical type I EGFR/HER2 
inhibitors TAK-285 and lapatinib also stabilized TRIB2 in vitro (Fig. 1F). The ATP-competitive 
covalent EGFR/HER2 inhibitors afatinib, neratinib and osimertinib (but not the unrelated covalent 
Bruton’s Tyrosine Kinase (BTK) inhibitor ibrutinib or the Type I EGFR-specific inhibitors erlotinib 
or gefitinib) destabilized TRIB2, similar to the PLK inhibitor GW804482X (Fig. 1F) and the dual 
EGFR/HER2 inhibitor GW569530A (fig. S1). As expected [15], purified TRIB1 (fig. S3A) was more 
thermostable than TRIB2 in the absence of kinase inhibitors (fig. S3B). However, it was not 
destabilised by afatinib, neratinib or osimertinib, although like TRIB2, destabilisation was evident in 
the presence of GW804482X (fig. S3C), in agreement with independent findings [56]. Compound 
effects were caused through pseudokinase targeting in the TSA, because no shift was elicited when 
the canonical kinase PKAc was compared in a side-by-side counter-screen, with dasatinib as a 
positive control (fig. S3D). The preclinical PLK inhibitors BI2536 and BI6727 (volasertib) had no 
discernible effects on TRIB2 stability in this assay, in contrast to the chemically distinct thiophene 
PLK inhibitor GW804482X (Fig. 1F).  
Afatinib, neratinib and osimertinib are covalent (type IV) inhibitors of EGFR/HER2 tyrosine kinases, 
interacting irreversibly with a conserved Cys residue in the canonical ATP-binding site [57]. The 
stabilization of TRIB2 by lapatinib, and the destabilization of TRIB2 by all three covalent 
EGFR/HER2 inhibitors, occurred in a dose-dependent manner (Fig. 1G and fig. S4). A C104Y TRIB2 
mutant was no longer destabilized by either afatinib or neratinib, but remained ‘sensitive’ to lapatinib 
TAK-285 and GW804482X based on thermal-protection (Fig. 1H and fig. S5A). Importantly, none of 
these latter compounds contain the electrophilic ‘warhead’ required for covalent interactions (fig.S2). 
Elution profiles from Superdex 200 were identical for WT and C104Y TRIB2 (fig. S5B), confirming 
that both proteins were monomeric species in solution, with estimated Mr of 45.3 kDa. C104Y TRIB2 
was also insensitive to thermal shift in the presence of ATP and EDTA (Fig. 1H and fig. S5C). These 
data suggest that the amino acid identity at TRIB2 position 104 is likely important both for ATP 
binding and interaction with covalent kinase inhibitors that induce TRIB2 destabilization in vitro.   
Mechanistic analysis of TRIB2 structural stability and TRIB2 ligand binding 
Structural analysis of TRIB1 by X-ray crystallography and small angle X-ray scattering led to the 
proposal of an in cis self-assembly model, whereby the unique C-terminal tail region, which contains 
the conserved ‘DQLVP’ motif, binds directly to the pseudokinase domain adjacent to the short C-
helix of TRIB1 [15, 16, 56]. To investigate whether this mechanism is also relevant in TRIB2, we 
generated a series of truncated proteins. These lacked either the N-terminal extension, which was 
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predicted to be disordered by both I-TASSER [58] and VSL2 [59], the C-terminal tail, or both N and 
C-terminal regions. We also generated a triple point mutant in which the ‘DQLVP’ tail motif, which 
is required for TRIB1 and TRIB2 cellular transformation in vivo [18], was mutated to a non-
functional ‘AQLAA’ sequence (Fig. 2A). Full-length (1-343) TRIB2, and TRIB2 lacking the N-
terminal domain (TRIB2 54-343), both exhibited similar Tm values of 39-40 °C (Fig. 2B). In contrast, 
deletion of the C-tail (TRIB2 1-318) changed TRIB2 stability, with Tm values falling to ~37°C, 
diagnostic of a destabilized TRIB2 conformation (Fig. 2B). Mutation of DQLVP to AQLAA further 
destabilized TRIB2, leading to a Tm value of ~36 °C (Fig. 2B). Using this panel of recombinant 
TRIB2 proteins, we measured the relative effects of kinase inhibitors on TRIB2 stability. Consistent 
with a lack of effect on compound interactions, deletion of the TRIB2 N-terminal region had no effect 
on Tm values induced by any compound. However, removal of the C-tail region (54-318 and 1-318 
mutants) abolished afatinib and neratinib-induced TRIB2 destabilization, but had a negligible effect 
on GW804482X binding (Fig. 2C). Consistently, destabilization by afatinib was also completely 
abolished in the AQLAA triple mutant, whereas neratinib effects were reduced by >50%. Notably, 
neither the destabilizing effect of GW804482X, nor the stabilizing effects of lapatinib or TAK-285 
differed between any of the TRIB2 proteins evaluated. These results suggest a very similar 
destabilizing mechanism induced by covalent EGFR/HER2 ligands via displacement of the TRIB2 C-
tail, which is a unique feature of Tribbles pseudokinases [13, 15].  
To evaluate whether the EGFR/HER2 ligand afatinib targeted unique Cys residues in the TRIB2 
pseudokinase domain (Fig. 1A), we performed mass spectrometry (MS) analysis to evaluate protein 
modification. As detailed in fig. S6A, incubation of TRIB2 with a 5-fold molar excess of afatinib led 
to covalent interaction with Cys 96 in TRIB2. A doubly charged chymotryptic product ion 
representing the TRIB2-derived DISC96Y:afatinib peptide adduct at m/z 543.2 (fig. S6A) and the 
isotopic ratios of the 35Cl or 37Cl-containing peptide ions unequivocally confirmed Cys96 as a site of 
TRIB2 binding (fig. S6B). Having confirmed an intact mass for recombinant full-length TRIB2 of 
43,587.09 Da, very similar to the predicted mass of 43,587.22 Da (fig. S6C), we were also able to 
ascertain that pre-incubation with afatinib generated covalent adducts containing predominantly either 
1 or 2 molecules of afatinib. There was also some evidence for tri and tetra-modified TRIB2 adducts 
(fig. S6D). We next examined afatinib interaction with TRIB2 by Microscale Thermophoresis (MST), 
a biophysical technique for quantification of reversible biomolecular interactions [60]. This revealed 
an interaction between fluorescent NTA-coupled His-TRIB2 and two compounds, which could be 
fitted to reversible binding with Kd values of ~16 M for afatinib and ~20 M for TAK-285 (figs. 
S7A, B). A sub-micromolar interaction between MCL-1 and A1210477 served as a positive control 
[61]. In agreement with MS data (fig. S6), we therefore propose initial (reversible) binding of the 
ATP-competitive afatinib ligand [62, 63], prior to subsequent formation of a covalent adduct(s) with 
the TRIB2 pseudokinase domain. We also evaluated the potential interaction of afatinib and neratinib 
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using TRIB2 modelled on the C/EBP-bound ‘SLE-in’ conformation from TRIB1 [13, 56] and 
compared it to the known afatinib target EGFR (in a ‘DFG-in’ conformation) using AutoDock Vina 
[64]. Docking of covalent inhibitors revealed a putative binding pocket formed by residues from the 
vestigial TRIB2 C-helix, including Cys96, and the 3 strand (fig S8A). Afatnib and neratinib dock in a 
structurally similar pose in which the enamine beta carbon orients towards the sulfhydryl group of 
Cys96. This docking pose, however, is distinct from afatinib bound crystal structure of EGFR, where  
Cys797 is located in the D-helix. We performed molecular dynamics simulations (fig. S8B) on the 
docked complexes to assess the feasibility of the binding poses. Both afatinib and neratinib remained 
stably bound to TRIB2 for nearly 17 ns, suggesting that the binding poses are favorable and feasible. 
[65]. The enamine beta carbon remained within 3-5 Å of the Cys96 sulfur atom for the majority of the 
simulation. Given the rapid nature of the thiol-ene reaction coupled with the proximity of reactants, 
we believe that this time frame offers sufficient time for the formation of a covalent bond [66], which 
we confirmed by MS analysis. 
To validate the biochemical importance of Cys residues for afatinib binding, we next examined 
interaction with TRIB2 in which two Cys amino acids were mutated to non-thiol containing Ser 
residues. Individual or combined mutation of Cys96 and Cys104 to a Ser residue had no effect on the 
thermal stability (Tm) of the purified TRIB2 proteins (Fig. 2D), in contrast to the highly stabilizing 
effect of a Tyr at position 104 (Fig. 1B and fig. S5C). However, individual or joint mutation of 
Cys96and Cys104 to Ser severely blunted the destabilizing effect of afatinib and neratinib on TRIB2, in 
contrast to the non-covalent TRIB2 ligand GW804482X or the EGFR/HER2 stabilizing compounds 
lapatinib and TAK-285 (Fig. 2E). Taken together, these findings confirm that covalent EGFR/HER2 
compounds elicit effects on TRIB2 through Cys96 and/or Cys104. 
Evaluation of TRIB2 interactors in human cells 
To evaluate TRIB2 targeting by compounds in living cells, we generated a polyclonal TRIB2 
antibody and an isogenic stable HeLa cell line expressing TET-inducible FLAG-tagged human 
TRIB2. Polyclonal TRIB2 antibodies were equally efficient at recognising recombinant His-FLAG-
TRIB2 and cellular FLAG-TRIB2 as a commercial monoclonal FLAG antibody (fig. S9A). We also 
constructed a stable HeLa cell line expressing low levels of inducible FLAG-TRIB2 (fig. S9B). We 
estimated that ~1 ng of TRIB2 was expressed in 40 g of whole cell lysate in the presence of TET, by 
comparing known amounts of recombinant His-FLAG-TRIB2 protein (fig. S9B).  
To quantify effects of TRIB2 expression on canonical signaling in model cells, we evaluated AKT 
phosphorylation. AKT became phosphorylated in stable HeLa cells after serum stimulation in the 
absence of TET (Fig. 3A). TRIB2 expression led to the appearance of a TRIB2 doublet 
(phosphorylation confirmed in the upper band by lambda phosphatase treatment, fig. S10), and a 
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marked increase in the extent and duration of AKT phosphorylation at Ser473. Using this HeLa cell 
model, we next evaluated the effects of small molecule inhibitors on TRIB2 signaling, by comparing a 
panel of in vitro TRIB2 destabilizing ligands discovered by DSF (afatinib, neratinib and osimertinib) 
with a series of control compounds. Brief (4h) exposure of TRIB2-expressing cells to afatinib led to a 
specific decrease in TRIB2 protein expression. All of the compounds evaluated are EGFR or 
EGFR/HER2 signaling pathway inhibitors, and consistently they all blocked ERK phosphorylation at 
these concentrations (Fig. 3B); any unique effects of drugs amongst this panel are therefore likely to 
be ‘off-target’ to EGFR/HER2. We next incubated cells for increasing lengths of time with afatinib. A 
rapid, time-dependent, elimination of TRIB2 protein was evident when cells were exposed to this 
drug, in contrast to DMSO controls in which TRIB2 protein remained relatively stable during the 
experiment (Fig. 3C), as expected [19]. To evaluate intracellular interaction between TRIB2 and 
kinase inhibitors, we exposed HeLa cells expressing TET-inducible FLAG-TRIB2 to each compound, 
and quantified TRIB2 thermal stability in the cell extracts using a cellular TSA (fig. S11) [67]. 
Consistently, FLAG-TRIB2 was destabilized more rapidly than DMSO and erlotinib-treated controls 
in the presence of afatinib, becoming undetectable in extracts heated to 45 °C (fig. S11). This was 
distinct from lapatinib, which partially stabilized TRIB2 in cell extracts, consistent with our in vitro 
analysis (Fig. 1F).  
Afatinib interacts with TRIB2 through a biochemical Cys-based mechanism, so we generated isogenic 
TET-inducible C96S or C96/104S TRIB2 mutant stable cell lines (fig. S12) and evaluated the effects 
of afatinib on exogenous TRIB2 stability. Afatinib (but not lapatinib or TAK-285) induced dose-
dependent loss of TRIB2 in WT-TRIB2 cells, which was partially prevented for C96S, and 
completely abolished in C96/104S TRIB2-expressing cells (quantified in Fig. 4A, right panels), 
demonstrating unequivocally that afatinib binds to TRIB2 in cells. Furthermore, afatinib (but not 
TAK-285 or erlotinib) treated WT-TRB2 cells exhibited a marked decrease in AKT Ser473 
phosphorylation, and this effect was abrogated in C96/104S TRIB2-expressing cells (Fig. 4B). 
Importantly, afatinib, TAK-285 and erlotinib all blocked ERK phosphorylation in WT and C96/104S-
TRIB2 isogenic cell lines, consistent with ‘on-target’ inhibition of their shared EGFR target (Fig. 4B).  
To investigate the mechanism of TRIB2 destabilization by afatinib, we added the drug to WT-TRIB2 
expressing HeLa cells in the presence of the proteasome inhibitor MG132, which partially rescued 
TRIB2 degradation after both rapid and prolonged exposure to afatinib (Fig. 4C). This finding is 
consistent with previously reported proteasome-dependent TRIB2 turnover [68]. We further evaluated 
this mechanism using a range of MG132 concentrations and the clinical proteasome inhibitor 
bortezomib (Fig. 4D) [21]; under both conditions, afatinib-mediated destabilization of TRIB2 was 
decreased. This effect was in contrast to afatinib-induced TRIB2 destabilization, which was still 
observed in the presence of non-specific inhibitors of autophagy (AICAR) and lysosomal degradation 
(chloroquine) (Fig. 4D). Our observations are in line with published findings, which suggest that 
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TRIB2 fate is dependent upon turnover by the ubiquitin proteasome system (UPS) in human cancer 
cells [19, 69]. However, the (non-covalent) TRIB1 and TRIB2-destabilizing ligand GW804482X did 
not induce TRIB2 degradation in cells after a 4-hour incubation period, in contrast to proteasome-
dependent degradation induced by the same concentration of afatinib (fig. S13). 
High levels of TRIB2 expression drive AML in vivo by inhibiting myeloid differentiation and 
promoting proliferation [18, 35]. However, endogenous TRIB2 expression has only previously been 
analysed in a few cell types, in large part due to a lack of reliable TRIB2 reagents. Using our TRIB2 
antibody, we evaluated endogenous expression of TRIB2 in the clinically-relevant U937 AML cell 
model (Fig. 5A), and established that acute (4 h) exposure to afatinib, but not lapatinib or erlotinib, 
decreased TRIB2 protein levels in a dose-dependent manner (Fig. 5A). Consistent with their ability to 
inhibit EGFR signaling, all three compounds completely blocked ERK phosphorylation. We next 
established dose-dependent effects on both TRIB2 expression and AKT Ser473 phosphorylation in 
afatinib-treated U937 cells (Fig. 5B). Importantly, these effects were tightly correlated with apoptotic 
induction of caspase 3 cleavage, but only at afatinib concentrations that also induced TRIB2 
degradation and concomitant loss of AKT Ser473 phosphorylation (Fig. 5B). To determine the impact 
of afatinib treatment on U937 cell viability we quantified cellular cytotoxicity after 72 h exposure 
(Fig. 5C). Afatinib (and neratinib) reduced cell viability with sub-micromolar IC50 values, whereas 
EGFR inhibitors erlotinib and gefitinib and the dual EGFR/HER2 inhibitor TAK-285, were 10-20 
fold less effective when compared side-by-side (Fig. 5C). As these compounds do not induce cellular 
TRIB2 destabilization, AKT activation or caspase 3 activation, our data suggest that the TRIB2-
destabilizing ligands afatinib and neratinib possess an enhanced ability to kill AML-derived cells [50].  
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DISCUSSION: 
A ligand-targetable regulatory mechanism for human TRIB2 
It is now accepted that signaling outputs can be controlled by non-enzymatic components, 
exemplified by mechanistically-related families of pseudoenzymes such as pseudokinases [46]. In the 
present study, we sought to target the cancer-associated pseudokinaseTRIB2 with a small molecule; 
initially the intention was to establish the validity of this approach for this class of pseudokinase, but 
subsequently we were also able to evaluate the effects of TRIB2 compound engagement in intact 
human cells. To discover TRIB2 ligands, we exploited an unbiased TRIB2 and TRIB1 thermal shift 
assay [40, 48], and identified multiple chemical classes of dual EGFR/HER2 (but not monovalent 
EGFR) inhibitors. One group of (ATP-competitive) kinase inhibitor induced stereotypical (positive) 
thermal shifts in TRIB2, consistent with binding in the atypical TRIB2 nucleotide-binding site [48]. A 
second group of chemical ligands induced TRIB2 (but not TRIB1) destabilization, and although 
initially unexpected, this could be explained mechanistically by a compound-induced, Cys-directed, 
covalent effect in which the TRIB2 pseudokinase domain became uncoupled from its own C-tail. A 
similar mechanism has been proposed to explain thermally-distinct conformers that exist in TRIB1, 
which shares ~70% identity with TRIB2 in the pseudokinase domain and a very similar C-tail motif 
[16]. Deletion of the TRIB1 C-tail also leads to the destabilization of the TRIB1 pseudokinase domain 
[15], similar to destabilizing effects observed for TRIB2 1-318 and 54-318 deletion mutants and an 
AQLAA mutant. These data allow us to propose that pseudokinase-domain docking to the C-terminal 
tail generates a thermally-stable conformation in both TRIB1 and TRIB2, and in the case of TRIB2, 
that this dynamic interaction can be targeted with covalent ATP-competitive covalent kinase 
inhibitors, which induce a structural pseudokinase conformation associated with decreased stability in 
vitro.  
How do covalent EGFR/HER2 inhibitors target TRIB2? 
We focused our studies on electrophilic type IV kinase inhibitors, since they were likely to bind to 
TRIB2 via a covalent mechanism, which is amenable to comparative chemical and mutational 
analysis [31, 70]. Using a combination of techniques, we confirmed that at-least two highly conserved 
TRIB2 Cys residues are targets of the ATP-dependent tyrosine kinase inhibitor afatinib [71] in vitro. 
Both TRIB2 Cys-residues are uniquely located within the distorted C-helix (Fig. 1A). In most 
canonical kinases, including EGFR family members, positioning of this helix is critical for catalysis 
and switching between inactive and active enzyme conformations, both of which can be targeted with 
small molecules [72]. Dynamic helix positioning is known to be generally important for interactions 
with kinase inhibitors, some of which recognise ‘inactive’ conformations in kinases in which the C 
helix adapts to permit compound binding, as established for HER2 [73]. The conformation of the 
 12 
flexible C-helix relative to the ATP binding P-loop also creates an allosteric binding pocket in 
canonical kinases such as ERK1/2 that can be targeted with selective non ATP-competitive inhibitors 
such as SCH772984, which possesses slow off-rate kinetics [74]. In TRIB2, a unique disposition of 
Cys residues (Fig. 1A) makes it vulnerable to destabilization by the EGFR/HER2 covalent inhibitors 
afatinib, neratininb and osimertinib in vitro, which all undergo Michael addition to a conserved Cys 
residue in the ATP-binding site of EGFR-related tyrosine kinases (Cys797 in EGFR, Cys805 in HER2 
and Cys803 in HER4) [61]. Afatinib also demonstrates low, but detectable, affinity for the ATP-
binding pseudokinase domain of HER3 [75, 76], which possesses a non-modifiable Ser residue 
(Ser794) at the equivalent position as Cys797 of EGFR, and assumes a pseudo ‘active’ catalytic 
conformation, despite possessing exceptionally low, or zero, kinase activity [76, 77]. At nanomolar 
cellular concentrations, afatinib appears relatively specific for EGFR and HER2 in cells, although at 
low micromolar concentrations other canonical kinases also appear to be targeted [9]. Moreover, 
osimertinib possesses cross-reactivity with both kinase [9] and non-kinase targets [78], including the 
lysosomal cathepsin proteases. In the absence of a high-resolution TRIB2 pseudokinase crystal 
structure, we do not yet know the conformation(s) relevant for small molecule interaction, although 
the TRIB2 N-lobe has both shared (SLE motif) and distinct (Cys96 and Cys104) features compared to 
TRIB1, TRIB3 and STK40 [15], and TRIB1 can adopt at least two conformations, one of which 
(‘SLE-in’) appears vulnerable to small molecule compounds [56]. This is reflected by subtle 
biochemical differences in the ability of TRIB2 to bind to ATP, which likely predisposes it to C-helix 
targeting by EGFR/HER2 kinase inhibitors (fig. S8). None of the EGFR family members possess a 
Cys residue in the C-helical region conserved in TRIB2, and the overall identity between HER2 and 
TRIB2 in the (pseudo)kinase domain is very low indeed (~22%). We therefore believe that our 
discovery of TRIB2 binding to covalent inhibitors such as afatinib owes as much to the availability of 
reactive Cys residues adjacent to a unique allosteric pocket in the TRIB2 pseudokinase domain as to 
their relatively low affinity for the vestigial ATP-binding site. Our work builds on previous studies in 
which pseudokinase domains have been targeted with small molecule kinase ‘inhibitors’ [3]. 
Examples include the ligand TX1-85-1 [8], which binds covalently to Cys721 in the roof of the ATP 
site (inducing HER3 degradation in cells) and recently described non-covalent JAK2 JH2 
(pseudokinase) domain ligands, whose binding mode has been confirmed through structural analysis 
[79, 80]. 
In the course of compound screening, we discovered that unrelated classes of ATP-competitive dual 
EGFR/HER2 ligands, including thienopyrimidines [55] and thiazolylquinazolines [53] also bound to 
TRIB2 in vitro. In contrast to destabilization (a feature of covalent TRIB2 ligands) these compounds 
stabilize TRIB2 in vitro, similar to lapatinib and the pyrrolo[3,2-d]pyrimidine EGFR/HER compound 
TAK-285, which can bind to HER2 in an active-like conformation [81]. This might be equivalent to 
the thermostable TRIB2 generated by compound binding or after C104Y substitution. Moreover, 
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evidence for a stabilized TRIB2:lapatinib complex was also established in cell extracts using cellular 
thermal stability assay (CETSA, fig. S11). Of relevance, the non-covalent ligands lapatinib and TAK-
285 did not induce TRIB2 degradation in cells. However, previous studies demonstrated that lapatinib 
can deprive HER2 of an interaction with the Hsp90-Cdc37 system, leading to time-dependent HER2 
degradation at micromolar concentrations [82]. Like HER2, the cellular mechanism by which TRIB2 
stability is regulated is proteasome-based (Fig. 4), and we speculate that an afatinib-induced 
conformational change might induce TRIB2 ubiquitination, or negatively regulate interaction with an 
unknown stabilizing factor(s), similar to the effects of Hsp90 inhibitors towards the stability of Cdc37 
kinome clients [83-85]. Consistently, TRIB2 abundance is itself stimulated by ubiquitination [19, 68, 
69], and future work will attempt to correlate TRIB2 small molecule interactions with dynamic 
changes in ubiqutination.  
The future: Targeting TRIB2 in cancer and beyond 
The finding that TRIB2 stabilizing and destabilizing cell permeable ligands can be discovered by 
simple DSF profiling is an important advance for the evaluation of compounds that target this, and 
other, catalytically-deficient pseudokinases. The interaction of TRIB2 with both covalent and non-
covalent clinical ligands confirms our original hypothesis, which stated that the TRIB2 pseudokinase 
represents a bona fide drug target [5]. We found that conserved Cys residues in TRIB2 make it 
vulnerable to known families of small molecule kinase inhibitors that were originally developed as 
nanomolar covalent inhibitors of the tyrosine kinases EGFR and HER2. Such dual-targeting suggests 
shared features between signaling-relevant (‘active’) conformations in the ATP-site of both TRIB2 
and EGFR/HER2, which generates reciprocal compound interactions. Conserved Cys residues in the 
atypical TRIB2 C-helical region most likely represent an additional form of selectivity filter, which 
permits targeting of TRIB2 by covalent classes of EGFR/HER2 inhibitor at micromolar 
concentrations in cells. Based on this mechanism, a lack of equivalent Cys residues in other 
pseudokinases, including the related TRIB1 and TRIB3, likely prevents them from interaction with 
covalent inhibitors such as afatinib in this manner.  
Using a chemical genetic approach, we provide strong evidence that afatinib induces on-target effects 
through TRIB2 stability and AKT signaling in human cancer cells. Importantly, cellular signaling 
modulated by afatinib was prevented by mutation of two unique TRIB2 Cys residues, confirming a 
meaningful TRIB2 drug interaction in cells.  Drug interaction was also validated by DSF, MS, MST 
and by employing in-cell TSA (CETSA) approaches with exogenous TRIB2. Finally, we established 
that afatinib (and neratinib) exhibit sub-micromolar toxicity in the human AML model cell line U937, 
where they are 10-20 fold more effective at cell killing compared to equipotent EGFR/HER2 or 
EGFR inhibitors [72], which do not degrade TRIB2 but still block ERK activation. U937 cells have 
previously been shown to be hypersensitive to TRIB2 siRNA knock-down [68], strengthening the 
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case that the TRIB2 pseudokinase is rate-limiting for cell survival in this context. Experimental ‘on-
target’ effects of covalent TRIB2-destablising agents were confirmed using chemical genetics and a 
Cys-mutant TRIB2 pseudokinase allele, similar to classical ‘drug-resistance’ approaches developed 
for compound target validation in the kinase inhibitor field [86-89].   
CONCLUSION: 
Our work demonstrates that covalent EGFR/HER2 inhibitors such as afatinib possess TRIB2 
degrading-activity in human cells at micromolar concentrations, in a similar range to those reported 
for other destabilizing kinase inhibitors, including the covalent EGFR/HER2 drug neratinib [90]. 
Although we cannot rule out simultaneous dual effects of afatinib on both TRIB2 destabilisation and 
ERK/AKT pathway inhibition contributing to cellular phenotypes, we provide clear evidence that 
TRIB2-binding is required for TRIB2 destabilization and AKT regulation in cells. Should an 
appropriate concentration of drug permit a direct TRIB2 interaction, an ‘off-target’ TRIB2-dependent 
phenotype might be relevant to compound efficacy (or side-effects) in patient groups exposed to high 
concentrations of covalent EGFR/HER2 inhibitors. Many severe side effects of drugs are only 
detected after long-term clinical use, potentially leading to their withdrawal [91], and covalent drugs 
have the potential to accumulate to relatively high concentrations in cells. For example, toxic side-
effects such as diarrhea and vomiting induced by the EGFR/HER2 inhibitors lapatinib [92] and 
afatinib [93] are well-established in clinical patient cohorts. Based on our mechanistic studies, it will 
be interesting to develop ELISA-based procedures to quantify effects of these drugs on TRIB2 protein 
stability in clinical samples obtained from drug-exposed patients, as part of broader proteomics 
approaches to establish all the intracellular targets of these compounds. Our study also provides 
impetus for generating improved (ideally TRIB2-specific) covalent ligands that induce TRIB2 
degradation at much lower (nanomolar) concentrations, ideally by synthesising compounds in which 
the effects of eliminating or preserving EGFR/HER2 inhibition can be compared side-by-side. In the 
latter case, simultaneous elimination of TRIB2 and inhibition of the ERK-signaling pathway could be 
a polypharmacological asset, especially if TRIB2-dependent drug-resistance in tumor cells [39, 50] 
can be modulated by EGFR/HER2 inhibition. Taken together, our data establish a new paradigm for 
the pharmacological evaluation of agents that interfere with TRIB2-based signaling, and raises the 
intriguing possibility that dual EGFR/HER2 inhibitors might be employed as TRIB2-degrading agents 
in research, and possibly clinical, contexts. This information might also be exploited in the future for 
targeting a variety of TRIB2-overexpressing solid [94, 95] and haematological [21, 68] tumors. 
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MATERIALS AND METHODS: 
Chemicals, reagents, antibodies and TRIB2 small molecule screen 
Tetracycline (TET) and doxycycline, MG132, AICAR and chloroquine were purchased from Sigma. 
Afatinib, neratinib, osimertinib, ibrutinib, erlotinib, lapatinib, TAK-285, BI2536, BI6727, gefitinib 
and bortezomib were purchased from LC laboratories or Selleck. Total AKT, pSer 473 AKT, pThr 
308 AKT, total ERK1/2, dual pThr 202/pTyr 204 ERK1/2, cleaved Caspase 3 and -tubulin 
antibodies were purchased from New England Biolabs and employed as previously described [51, 96]. 
6His-HRP and α-FLAG antibodies were purchased from Sigma, GAPDH antibody was purchased 
from Proteintech and a polyclonal rabbit α-TRIB2 antibody was raised towards a unique N-terminal 
human TRIB2 sequence and affinity purified prior to evaluation with recombinant TRIB2 and a 
variety of human cellular extracts.  
The PKIS chemical library (designated as SB, GSK or GW compounds) comprises 367 ATP-
competitive kinase inhibitors, covering ~30 chemotypes (~70% with molecular mass <500 Da and 
clogP values <5) that were originally designated as ATP-competitive inhibitors of 24 distinct protein 
kinase targets, including multiple EGFR and HER2 tyrosine kinase classes [52]. Compounds were 
stored frozen as 10 mM stocks in DMSO. For initial screening, compounds were pre-incubated with 
TRIB2 for 10 minutes and then employed for DSF, which was initiated by the addition of fluorescent 
SYPRO Orange. For dose-dependent thermal-shift assays a compound range was prepared by serial 
dilution in DMSO, and added directly into the assay to the appropriate final concentration, as 
previously described [97] [Add Byrne BJ papers]. All control experiments contained 2% (v/v) DMSO, 
which had essentially no effect on TRIB2 stability.   
Cloning, Site Directed Mutagenesis and recombinant protein production  
pET30 6His-TRIB2 (and various deletion or amino acid substitution constructs, including an N-
terminal FLAG-tagged TRIB2, termed His-FLAG-TRIB2), and pET30a 6His-PKAc, which encodes 
catalytically-active cAMP-dependent protein kinase domain, have been described previously [40, 49]. 
Full length TRIB2 was also cloned into pOPINJ to generate a His-GST-TRIB2 encoding construct for 
Glutathione-S-transferase (GST) pull-down assays. MCL-1 and A-1210477 were prepared as 
described [61]. TRIB1 (84-372) was a kind gift from Dr. Peter Mace, and was purified as described 
previously for TRIB2 [40]. Briefly, protein expression was induced in BL21(DE3) pLysS bacteria 
with 0.4 mM IPTG, and after overnight culture at 18°C, proteins were purified to near homogeneity 
using an initial affinity step (immobilised metal affinity chromatography (IMAC) or glutathione-
sepharose chromatography) followed by size exclusion chromatography (16/600 Superdex 200) in 
appropriate buffers. S473D 6His-AKT1 (DU1850, amino acids 118-470), either active (PDK1-
phosphorylated to a specific activity of 489 U/mg) or inactive, were purchased from the DSTT 
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(University of Dundee), and stored at -80°C prior to analysis. Site directed mutagenesis was 
performed as previously described [98], using KOD Hot Start DNA polymerase (Millipore) and 
appropriate mutagenic primer pairs (sourced from IDT). All plasmids were Sanger-sequenced across 
the entire coding regions to confirm expected codon usage. 
Differential Scanning Fluorimetry (DSF) 
Thermal-shift assays were performed using an Applied Biosystems StepOnePlus Real-Time PCR 
instrument using a standard DSF procedure previously developed and validated for the analysis of 
kinases [47, 49] and pseudokinases [48]. All proteins were diluted in 20 mM Tris/HCl (pH 7.4), 100 
mM NaCl and 1 mM DTT to a concentration of 5 μM and then incubated with the indicated 
concentration of compound in a total reaction volume of 25 μL, with final concentration of 2% (v/v) 
DMSO. SYPRO Orange (Invitrogen) was used as a fluoresecence probe. The temperature was raised 
in regular 0.3 °C intervals from 25°C to 95°C. Compound binding experiments were assessed in 
duplicate and then reported relative to DMSO controls. 
Mass Spectrometry analysis of TRIB2 afatinib binding 
To evaluate TRIB2 binding in vitro, afatinib was incubated for 15 min with purified 6His-TRIB2 at a 
1:10 molar ratio, then denatured with 0.05 % (w/v) RapiGest SF (Waters, UK) and digested with 
chymotrypsin (1:20 protease:protein (w/w) ratio) for 16 h at 25 °C. RapiGest hydrolysis was induced 
by the addition of triflouroacetic acid (TFA) to 1 % (v/v), incubated at 37 °C for 1h. Insoluble product 
was removed by centrifugation (13, 000 x g, 20 min).  Reversed-phase HPLC separation was 
performed using an UltiMate 3000 nano system (Dionex) coupled in-line with a Thermo Orbitrap 
Fusion Tribrid mass spectrometer (Thermo Scientific, Bremen, Germany). 500 fmol digested peptides 
were loaded onto the trapping column (PepMap100, C18, 300 μm × 5 mm), using partial loop 
injection, for 7 min at a flow rate of 9 μL/min with 2% (v/v) MeCN, 0.1% (v/v) TFA and then 
resolved on an analytical column (Easy-Spray C18 75 μm × 500 mm, 2 μm bead diameter column) 
using a gradient of 96.2% A (0.1% (v/v) formic acid (FA)): 3.8% B (80% (v/v) MeCN, 0.1% (v/v) 
FA) to 50% B over 35 min at a flow rate of 300 nL/min. MS1 spectra were acquired over m/z 400 – 
1500 in the orbitrap (60 K resolution at 200 m/z). Data-dependent MS2 analysis was performed using 
a top speed approach (cycle time of 3 s), using higher-energy collisional dissociation (HCD) and 
electron-transfer and higher-energy collision dissociation (EThcD) for fragmentation, with product 
ions being detected in the ion trap (rapid mode). Data were processed using Thermo Proteome 
Discoverer (v. 1.4) and spectra were searched in MASCOT against the E. coli IPI database with the 
added sequence of full-length 6His-TRIB2 (1-343). Parameters were set as follows: MS1 tolerance of 
10 ppm, MS/MS mass tolerance of 0.6 Da, oxidation of methionine and afatanib binding at cysteine as 
variable modifications. MS2 spectra were interrogated manually.  
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To evaluate the interaction between afatinib and intact TRIB2 protein, TRIB2 was incubated with 
afatinib as above, and then desalted using a C4 desalting trap (Waters MassPREP™ Micro desalting 
column, 2.1 × 5 mm, 20 μ m particle size, 1000 Å pore size). TRIB2 was eluted with 50 % (v/v) 
MeCN, 0.1 % (v/v) formic acid. Intact TRIB2 mass analysis was performed using a Waters nano 
ACQUITY Ultra Performance liquid chromatography (UPLC) system coupled to a Waters SYNAPT 
G2. Samples were eluted from a C4 trap column at a flow rate of 10 µL/min using three repeated 0-
100 % acetonitrile gradients. Data was collected between 400 and 3500 m/z and processed using 
MaxEnt1 (maximum entropy software, Waters Corporation).  
 
TRIB2 modeling and compound docking 
The structure model of human TRIB2 pseudokinase domain [13]  (UniProt ID: Q92519) (residues 58-
308) was built with MODELLER [99] using a crystal structure of TRIB1 pseudokinase in the open 
‘SLE-in’ conformation [56] as a template. The homology model was subjected to energy 
minimization using the Rosetta Relax protocol [100]. The chemical structures of afatinib (CID 
10184653) and neratinib (CID 9915743) were retrieved from PubChem. Afatanib and neratinib were 
docked to our TRIB2 model using AutoDock Vina [62] with an exhaustiveness of 100, rigid body, 
and a search space centered on Cys96. Top poses where identified where the enamide group localizes 
near the Cys96 sulfhydryl moiety. For comparison, we employed a crystal structure of EGFR in 
complex with afatinib (PDB: 4g5j). Structural gaps were closed using RosettaRemodel [101] using 
with settings. The covalently-bound afatinib was removed from the structure and allowed to re-dock 
with AutoDock Vina using the same parameters from TRIB2, with the exception of search space 
being centered on EGFR Cys797. Top poses were identified where the enamide group localized near 
the Cys797 sulfhydryl moeity. For molecular dynamics simulations, TRIB2 and EGFR binding modes 
were parameterized with GROMACS 5.1.3. Afatinib and neratinib were parameterized using 
ACPYPE [102].  Protein was fixed with amber99sb-ildn force field and solvated with TIP3P water 
model in a dodecahedron box at least 1 nm larger than the protein in all directions. Sodium and 
chloride ions were added to neutralize the system. Neighbor lists for non-bonded interactions were 
maintained by the Verlet cutoff scheme and long-range electrostatics were calculated by the Particle 
Mesh Ewald method. Energy minimization was performed with steepest descent followed by 
conjugate gradient until the total energy was under 100 kJ/mol/nm. The system was heated from 0 to 
310 K, then pressurized to 1 bar. Position restraint was applied to non-hydrogen atoms during 
equilibration. The production run was performed in 2 fs time-steps. Data visualization was performed 
in VMD and PyMOL. 
 
MicroScale Thermophoresis  
A Monolith NT.115 instrument (NanoTemper Technologies GmbH) was employed for MST analysis. 
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His-TRIB2 was initially labelled with a NanoTemper labelling kit; the fluorescent red dye NT-647 
was coupled via NHS chemistry to the N-terminal His-tag, placing the fluorophore away from the 
pseudokinase domain. For MST, the reaction was performed in 20 mM Bicine pH 9.0, 100 mM NaCl, 
5% glycerol, 0.05% Tween-20 and 2 % (v/v) DMSO. Fluorescent TRIB2 (~5 M) was kept constant 
in the assay, while final afatinib and TAK-285 concentration was titrated over a 3 nM and 50-100 M 
range. Near-saturation binding was achieved, allowing for an affinity to be estimated for the 
reversible interaction between afatinib, TAK-285 and fluorescent TRIB2. NT-647-linked MCL-1 and 
A-1210477 was employed as a positive control. 
Cell lines and reagents 
Flp-In T-REx parental HeLa cells (Invitrogen) were cultured in DMEM with 4 mM L-glutamine, 10 
% (v/v) Foetal Bovine Serum (FBS), Penicillin and Streptomycin (Gibco) as described [86]. To 
engineer Tetracycline (TET)-controlled expression of FLAG-tagged full length TRIB2 in human Flp-
In T-REx cell lines, the host plasmid pcDNA5/FRT/TO, encoding full length TRIB2 sequences (or 
appropriate amino acid substitution(s)), with a single N-terminal FLAG tag (1 g DNA per well in a 6 
well plate of cells) were co-transfected with 9 µg of pOG44 Flp-Recombinase Expression Vector 
using lipofectamine. Cells that had successfully integrated the FLAG-tagged TRIB2 sequence were 
stably selected with 200 μg/mL Hygromycin B, according to the manufacturer’s instructions. TET 
was added at a final concentration of 1 g/ml to medium in order to induce FLAG-TRIB2 expression. 
For transient transfection, 50% confluent HeLa cells were transfected with 40 g DNA per 10 cm dish 
for 48 h prior to lysis.  
For serum starvation, stable HeLa cells were grown until ~60% confluent in complete medium 
(+FBS), washed with PBS, and replaced with serum-free DMEM for 16 h. Cells were then incubated 
with DMEM containing 10% (v/v) FBS ± 1 g/ml TET for 16 h, followed by addition of appropriate 
inhibitor for 4h. All whole cell lysates were generated with modified RIPA buffer (see below). Non-
adherent AML-derived human U937 cells (which express high levels of endogenous TRIB2 protein) 
were supplied by Dr Karen Keeshan, University of Glasgow and were cultured as previously 
described [21].    
MTT cytotoxicity assay 
U937 cells were seeded in a 96 well plate at a concentration of 0.2 x 106 cells/mL, 18 hours prior to 
compound addition, which was performed in triplicate, with all experiments including a final 
concentration of 0.1% DMSO (v/v). To quantify U937 cell viability, metabolic activity was assessed 
72 h after compound exposure using an MTT assay (Abcam), as described previously [103]. Briefly, 
Thiazolyl blue tetrazolium bromide was dissolved in PBS and added to cells at a final concentration 
of 0.25 mg/mL and incubated at 37 °C for 3 hours. The reaction was stopped by the addition of 50 μL 
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of acidified 10% SDS, followed by reading of absorbance at 570 nm. Viability was defined relative to 
DMSO-containing controls incubated for the same period of time. 
Immunoblotting and CETSA 
HeLa and U937 whole cell lysates were generated using a modified RIPA buffer (50 mM Tris–HCl 
pH 7.4, 1 % (v/v) NP-40, 1 % (v/v) SDS, 100 mM NaCl, 100 nM Okadaic acid) supplemented with 
protease and phosphatase inhibitors (Roche), and brief sonication. For western blotting, samples were 
boiled for 5 min in sample buffer (50 mM Tris pH 6.8, 1% SDS, 10% glycerol, 0.01% Bromophenol 
Blue, 10 mM DTT). Subsequently, and between 40 and 120 g of total protein was resolved by SDS–
PAGE followed by transfer onto nitrocellulose membrane (BioRad). After blocking in pH TBS-T + 
5% milk, pH 7.4), primary and secondary antibodies were incubated in the same condition, and 
proteins were detected using HRP-conjugated antibodies and ECL reagent. Immunoblots were 
quantified using ImageJ software, as previously described [96]. For lambda phosphatase treatment, 40 
g FLAG-TRIB2 expressing stable cell extracts in lysis buffer without SDS and phosphatase 
inhibitors were incubated with 10 ng of purified -phosphatase for 30 min at 37°C prior to processing 
for western blotting. 
For in-cell CETSA we employed a previously published procedure [104]. Briefly, stable HeLa cells 
were incubated with TET for 16h to induce expression of FLAG-TRIB2, and at ~90% confluency, 
were incubated with 0.1% (v/v) DMSO or 100 M of the indicated compound for 1h. Intact cells were 
isolated by trypsinization (1 min) and resuspended in PBS, and then aliquoted into individual PCR 
tubes prior to heating at the indicated temperature in a PCR thermal cycler for 3 min. Cells were then 
placed on ice for 2 min and lysed by sonication, prior to centrifugation at 16,000 x g for 20 minutes at 
4°C. The soluble lysate was analysed for the presence of FLAG-TRIB2 and -tubulin by 
immunoblotting. 
Statistical analysis 
All experimental procedures were repeated in at least 3 separate experiments with matched positive 
and negative controls (unless stated otherwise). Results are expressed as mean ± SD for all in vitro 
experiments and data are expressed as the mean ± standard deviation. When applied, statistical 
significance of differences (*P ≤0.05) was assessed using a Students t-test for normally-distributed 
data. All statistical tests were performed using Prism 7 (GraphPad Software) 
SUPPLEMENTARY MATERIALS: 
Fig. S1. Discovery of multiple PKIS compounds as TRIB2 ligands. 
Fig. S2. Chemical structure of pre-clinical and clinical compounds evaluated in this study. 
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Fig. S3. Validation of DSF assay using TRIB1 and a PKAc counter-screen.  
Fig. S4. Thermal melting profiles of TRIB2 using DSF. 
Fig. S5. Analysis of C104Y mutation in TRIB2. 
Fig. S6. MS-based analysis of the covalent TRIB2:afatinib complex. 
Fig. S7. Microscale Thermophoresis (MST) assay. 
Fig. S8. Molecular docking analysis. 
Fig. S9. A new TRIB2 antibody for quantitative analysis of TRIB2 expression levels and 
stability. 
Fig. S10. Analysis of TRIB2 dephosphorylation in cell extracts. 
Fig. S11. TRIB2-binding to afatinib induces destabilization relative to DMSO in a whole cell 
thermal shift assay (CETSA). 
Fig. S12. Comparative protein expression analysis of stable HeLa FLAG-TRIB2 cell lines. 
Fig. S13. Lack of effect of the non-covalent TRIB1 and TRIB2 destabilizing ligand GW804482X 
on TRIB2 stability in TRIB2-expressing HeLa cells. 
Table S1. PKIS compound screening data for full-length TRIB2 
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FIGURE LEGENDS: 
Fig. 1. Full-length TRIB2 is a target for protein kinase inhibitors in vitro 
(A) (Top) Sequence alignment of human TRIB2, TRIB1, TRIB3 and STK40 highlighting Cys-rich 
residues (numbered in red) in the TRIB2 pseudokinase domain.  (Bottom) Recombinant proteins 
employed for in vitro analysis. 5 μg of the indicated purified proteins were resolved by SDS-PAGE. 
(B) Thermal denaturation profiles of recombinant proteins. A representative unfolding profile is 
shown.  Tm values (±SD) were obtained from 3 separate fluorescence profiling expereiments, each 
point assayed in duplicate. (C) The ability of GST-TRIB2 to interact with active (PDK1-
phosphorylated) or inactive (non PDK1-phosphorylated) S473D AKT1 was assessed by GSH-
sepharose pull-down followed by immunoblotting. PDK1 phosphorylated S473D AKT is 
phosphorylated on Thr308 (right panel), but binds much more weakly to TRIB2. ‘Master-mix’ input is 
shown in the left panel. (D) Transient transfection of TET-inducible FLAG-TRIB2 leads to increased 
AKT phosphorylation on Ser473. (E) TRIB2 DSF screen using PKIS. 5 µM His-TRIB2 was employed 
for all DSF analysis. ΔTm values were calculated for each compound (N=2). Scattergraph of data 
highlights a wide variety of compounds that either stabilize or destabilize TRIB2 in vitro. Cut off 
values of > + 3.5 °C and < - 2°C were used to designate ‘hits’. (F) Comparative DSF analysis of 
clinical and preclinical kinase inhibitors as potential TRIB2 ligands. LAP=lapatinib, TAK=TAK-285, 
AFA=afatinib, NER=neratinib, OSI=osimertinib, IBR=ibrutinib, ERL=erlotinib, GEF=gefitinib. (G) 
Dose-dependent analysis of thermal shifts induced by clinical TRIB2 ligands. Compounds were tested 
at 5, 10, 20, 40, 80 and 160 µM. (H) Profiling of TRIB2 and C104Y with selected inhibitors by DSF.  
Fig. 2. TRIB2 thermal stability is modulated through Cys binding to covalent inhibitors  
(A) (Top) Schematic cartoon of TRIB2 with domain boundaries numbered and cysteine residues 
highlighted (red). (Bottom) SDS-PAGE of 5 μg recombinant TRIB2 proteins. (B) Thermal 
denaturation profiles of 5 μM WT-TRIB2 (amino acids 1-343), three truncated variants and an 
AQLAA triple-point mutant. Representative curves for each protein and average Tm values (±SD) are 
shown calculated from N=3 experiments. (C) Thermal shift analysis of TRIB2 deletion and AQLAA 
proteins measured in the presence of a panel of compounds (20 M). The change in Tm value (Tm) is 
reported from N=3 experiments, each performed in triplicate, and the chemical structures of each 
compound are shown for comparison. AFA=afatinib, NER=neratinib, LAP= lapatinib, ERL=erlotinib. 
(D) Thermal denaturation profiles for purified TRIB2 and C96S, C104S and C96/104S proteins. (E) 
Thermal shift analysis of TRIB2 Cys-mutated proteins measured in the presence of a panel of 
compounds (20 µM). The change in Tm value (Tm) is reported from N=3 experiments.  
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Fig. 3: Afatinib promotes rapid degradation of FLAG-TRIB2 in an inducible HeLa model 
(A) Uninduced (-TET) or Tetracycline-induced (+TET) HeLa cells containing a stably integrated 
FLAG-TRIB2 transgene were serum starved for 16h prior to the addition of serum, and lysed at the 
indicated times. Whole cell extracts were blotted with FLAG antibody to detect FLAG-TRIB2, pSer 
473 AKT. Total AKT and total GAPDH served as loading controls. (B) A selection of clinically 
approved kinase inhibitors, including dual EGFR/HER2 and EGFR-specific compounds, were added 
to TET-induced cells at a final concentration of 10 μM. Stable cells were induced to express FLAG-
tagged TRIB2 with tetracycline for 16h prior to inhibitor treatment for 4 hours. AFA=afatinib, 
NER=neratinib, OSI=osimertinib, IBR=ibrutinib, LAP=lapatinib, ERL=erlotinib, GEF=gefitinib. 
Whole cell extracts were immunoblotted with FLAG, pERK, ERK or GAPDH antibodies. (C) Stable 
HeLa cells were incubated with TET for 16h, and then incubated with DMSO (top panels) or 10 µM 
afatinib (AFA, bottom panels) prior to lysis at the indicated time. 1h and 16h samples were pre-treated 
with lambda protein-phosphatase (PP) prior to SDS-PAGE. Whole cell extracts were immunoblotted 
with FLAG or GAPDH antibodies.   
Fig. 4. ‘On-target’ degradation of TRIB2 by afatinib: C96/104S TRIB2 double point mutant is 
resistant to degradation  
(A) The indicated concentration of afatinib, 25 M lapatinib or TAK-285 was incubated for 4 h with 
isogenic stable HeLa cells expressing FLAG-tagged WT-TRIB2, C96S or C96/104S TRIB2 (induced 
by TET exposure for 16h). After lysis, whole cell extracts were immunblotted with the indicated 
antibodies. FLAG-TRIB2 levels were quantified after exposure to 10, 15 and 20 µM afatinib relative 
to DMSO controls using ImageJ densitometry software (data amalgamated from N=3 independent 
biological replicates). (B) WT and C96/104S stable HeLa cell lines were subjected to serum block-
and-release protocol in the presence (+TET) or absence (-TET) of tetracycline. Subsequently, the 
indicated compounds (10 M) were added for 4 h prior to cell lysis and immunoblotting with the 
indicated antibodies. AFA=afatinib, ERL=erlotinib. (C) FLAG-tagged TRIB2 expressing HeLa cells 
were incubated with (0.1% v/v) DMSO or 10 μM afatinib, in the presence or absence of 10 M 
MG132 for 4 hours (left) or at the indicated time points (right) prior to lysis and processing for 
immunoblotting. (D) (Left) FLAG-TRIB2 expressing stable cells were incubated with the indicated 
concentration of MG132 in the presence or absence of 10 μM afatinib (AFA) for 4 h prior to cell lysis 
and immunoblotting. (Right) FLAG-TRIB2 expressing stable cells were incubated for 1h with 10 M 
MG132, 10 M bortezomib (BOR), 1 mM AICAR (AIC) or 50 M Chloroquine (CLQ) prior to the 
addition of 10 M AFA for an additional 4 h followed by lysis and immunoblotting with the indicated 
antibodies.  
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Fig. 5. Afatinib rapidly destabilizes endogenous TRIB2 and specifically induces caspase-3 
cleavage and U937 cytotoxicity 
(A) Endogenous TRIB2 is destabilized in human U937 cells in a dose-dependent manner after a 4 h 
exposure to AFA. Cells were incubated with either 0.1% (v/v) DMSO, the indicated concentrations of 
afatinib, or 10 μM lapatinib (LAP), 10 μM erlotinib (ERL) or 10 μM of the proteasome inhibitor 
bortezomib (BOR) for 4 h prior to lysis and immunoblotting of endogenous TRIB2, pERK or cleaved 
caspase 3. GAPDH served as a loading control. (B) Endogenous TRIB2 is destabilized after exposure 
to afatinib for 24h, concomitant with reduced AKT phosphorylation at Ser473. After cell collection and 
lysis, whole cell extracts were immunoblotted with the indicated antibodies. AKT and GAPDH served 
as loading controls and ERL and BOR were used at 10 μM. (C) The cytotoxicity of a panel of TRIB2-
destabilsing ligands (afatinib, AFA and neratinib, NER) were compared to EGFR inhibitors or the 
TRIB2 stabilizer TAK-285 (TAK). MTT assays were performed after 72 h compound exposure, with 
bortezomib (BOR) employed as a positive control. IC50 values (nM ± SD) are derived from N=3 
independent experiments, each performed in triplicate. Statistical analysis confirmed a significant 
difference in cytotoxicity between AFA and ERL (students t-test p value = 0.0104) BOR and ERL (p 
value = 0.0072) and NER and ERL (p value = 0.0104). 
 
 
 
